Oral solid dosage development is a chain of connected decisions.

The API sets the boundaries

Dose, solubility, particle size, morphology, flow, compactability, stability and sensitivity to moisture or heat influence almost every downstream choice. Development becomes faster when these constraints are made explicit before a formulation platform is selected.

Choose the process for the material

Direct compression is attractive when the blend can flow, feed and compact reliably. Roller compaction can improve handling without introducing water. Wet granulation can create stronger granules and content uniformity but adds liquid, drying and scale-up variables. Fluid-bed and continuous approaches create additional options. The correct route is the one that fits the API, dose, product target and future manufacturing environment.

Scale-up is not a larger laboratory batch

Equipment geometry, energy input, residence time, spray conditions, drying behavior, transfer losses and control ranges all change with scale. A robust formulation should tolerate these changes without becoming dependent on a narrow process window.

Technology transfer starts earlier than the transfer

The future site, equipment and control strategy should influence development well before formal transfer. That is the practical meaning of designing for industrialization rather than optimizing only for the development laboratory.